Myocardial Infarction News and Research

RSS

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Two Roche Diagnostic tests identified as transformative products for rapid uptake

Roche Diagnostics tests for suspected pre-eclampsia and heart attack have been recognized as ‘transformative’ and have been selected among only seven Rapid Uptake Products for the NHS.

From Roche Sequencing and Life Science 23 Oct 2018

Common antibodies associated with myocardial infarction

Levels of antiphospholipid antibodies, which are associated with rheumatic diseases, are also elevated in myocardial infarction without any autoimmune co-morbidity, a study from Karolinska Institutet in Sweden published in The Annals of Internal Medicine reports.

23 Oct 2018

The immune system also plays a key role in day-to-day function of healthy organs

The cells of the immune system sustain life by infiltrating infected and dmaged tissue and eliminating pathogenic microorganisms and cell debris.

19 Oct 2018

Researchers develop comprehensive molecular atlas of postnatal mouse heart development

Myocardial infarction is one of the most common causes of death in the Western world. Typically, MI is caused by the blockage of a coronary artery by an atherosclerotic plaque: as the oxygen supply of the heart drops, cell death occurs.

15 Oct 2018

Healthy gut microbiome shown to be important for recovery after heart attack

The community of microorganisms that live in the human gut has been shown to confer all kinds of health benefits. Now, an international team of researchers has shown in mice that a healthy gut microbiome is important for recovery after a heart attack.

10 Oct 2018

Appetite-suppressant drug reduces diabetes risk and increases remission rates of blood sugar

New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Berlin, Germany, and published in The Lancet, shows that the appetite-suppressant drug lorcaserin decreases risk of developing diabetes and increases the rates of remission of high blood sugar.

4 Oct 2018

Weight loss drug reduces risk of diabetes in patients with pre-diabetes, finds study

At the 2018 Meeting of the European Association for the Study of Diabetes, Brigham and Women's Hospital investigators from the Thrombolysis in Myocardial Infarction Study Group presented diabetes-related findings from CAMELLIA-TIMI 61, a clinical trial of overweight and obese patients designed to test lorcaserin, a weight loss drug manufactured by the trial's sponsor, Eisai Inc.

4 Oct 2018

UH pharmacologist receives NIH grant to improve kidney function in older people

Mohammad Asghar, associate professor of pharmacology at the University of Houston, has been awarded $459,000 from the National Institutes of Health/National Institute on Aging to improve kidney function in people 65 and older, a population at higher risk for developing impaired kidney function.

27 Sep 2018

Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE

Patients with venous thromboembolism carry a high risk of recurrence. Accordingly, a 16-year Danish prospective cohort study of nearly 74,000 patients with incident VTE concluded that the risk of recurrence is substantial.

25 Sep 2018

Clinical study shows efficacy, safety of novel drug-eluting stent with improved radiographic visibility

This first randomized clinical study of a polymer-coated zotarolimus-eluting stent (Resolute Onyx) that utilizes a novel thin-strutted metallic platform allowing for better x-ray visibility was shown to be non-inferior to an ultrathin-strutted bioresorbable polymer-coated sirolimus-eluting stent (Orsiro) that uses a cobalt-chromium strut platform.

25 Sep 2018

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial for FARXIGA, the broadest SGLT-2 inhibitor CVOT conducted to date.

24 Sep 2018

Celltrion and Emory University sign 'Incubation' agreement to develop new drug candidates for atherosclerosis

Celltrion, Inc. signed an 'Incubation' agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.

20 Sep 2018

ATS publishes new guideline focused on weight loss strategies for sleep apnea patients

A new guideline focused on the role of weight management in treating adult obstructive sleep apnea has been published online by the American Thoracic Society in the Sept. 15 American Journal of Respiratory and Critical Care Medicine.

19 Sep 2018

Digital games for CVD-related self-management improve exercise capacity and energy expenditure

A scoping review of studies on game interventions for cardiovascular diseaseself-management found that the use of digital games improved exercise capacity and energy expenditure significantly.

18 Sep 2018

ATS publishes new guideline on role of weight management in sleep apnea treatment

17 Sep 2018

Research shows novel approach for treatment of myocardial infarction

Myocardial infarction - commonly known as a heart attack - is still one of the main causes of death. According to the Federal Statistical Office, more than 49,00 people died of its consequences.

12 Sep 2018

New research considers current state of transradial access

The adoption of transradial access in the United States and internationally has been growing over the past few years.

11 Sep 2018

EC approves update of INVOKANA and VOKANAMET labeling to include changes to indication statement

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted approval to update the INVOKANA® and VOKANAMET® labeling to include changes to the indication statement for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

7 Sep 2018

New trial assesses criteria used to diagnose myocardial infarction

Results of the first randomized trial testing the criteria used to diagnose heart attack are presented today in a Hot Line Session at ESC Congress 2018 and published in The Lancet.

28 Aug 2018